A drug-resistant fungus threatens to overrun UK hospitals, sparking concerns about public health and safety.
Story Highlights
- *Candida auris* is spreading in UK hospitals, posing a public health threat.
- The fungus is resistant to multiple antifungal drugs, complicating treatment efforts.
- Outbreaks have been reported, especially affecting vulnerable populations in healthcare settings.
- Authorities are calling for improved surveillance and infection control measures.
Rapid Spread of *Candida auris* in the UK
The drug-resistant fungus *Candida auris* has become a significant concern in UK hospitals as it continues to spread rapidly. Initially identified in Japan in 2009, this multidrug-resistant fungus poses a substantial threat due to its resistance to multiple antifungal treatments and its ability to persist on surfaces. Outbreaks have been reported across healthcare settings, raising alarms about the effectiveness of current infection control measures.
The spread of *Candida auris* has been particularly alarming in hospital environments, where vulnerable patients are at an increased risk of infection. The fungus is known for colonizing the skin, especially in the groin and armpit areas, making it a formidable challenge for healthcare professionals tasked with controlling its spread. In the UK, fewer than 700 cases have been detected, but the trend suggests a potential rise in numbers.
Drug-resistant 'super fungus' that attacks groin and bum spreading through UK and can be transmitted by sex https://t.co/YVXCOuRljy pic.twitter.com/pAOZqmavvY
— Daily Star (@dailystar) November 25, 2025
Challenges in Diagnosis and Control
One of the critical challenges in combating *Candida auris* is its environmental persistence, which allows it to remain on surfaces and medical equipment long after the initial exposure. This persistence complicates efforts to eliminate the fungus from healthcare environments. Moreover, the fungus’s resistance to first-line antifungal drugs makes it difficult to treat, increasing the risk of severe infections and outbreaks.
The European Centre for Disease Prevention and Control (ECDC) has reported a sharp increase in cases across Europe, with 1,346 cases recorded in 2023 alone. The situation is compounded by difficulties in diagnosis, as *Candida auris* is often misidentified, leading to delayed treatments and increased morbidity and mortality rates among affected patients.
Calls for Urgent Action and Improved Measures
Authorities, including the UK Health Security Agency (UKHSA) and the ECDC, are calling for urgent action to address the spread of *Candida auris*. Improved surveillance, rapid detection, and robust infection control measures are crucial to contain the fungus. Enhancing laboratory capacity and reference testing in the UK and other countries is also vital to better manage the outbreaks.
Experts emphasize the need for a coordinated international response to this global health threat. Hospital infection control teams are urged to implement local containment strategies, while researchers focus on developing new antifungal agents and improving diagnostics. The ongoing rise in cases highlights the importance of continued vigilance and innovation in combating this persistent fungal threat.
Drug-resistant bacteria and fungi, such as Candida auris, are already entrenched in hospitals. Learn more here: https://t.co/FtXUBIn4ev
— Public Health Bulletin South Africa (@TheBulletin_SA) November 24, 2025
Sources:
ECDC confirms rapid spread of drug-resistant *Candidozyma auris* in European hospitals
Multidrug-resistant yeast cases rising rapidly, survey shows
UKHSA on *Candidozyma auris*: Fungal pathogen and emerging global health threat
Persistent challenges of *Candidozyma auris* in healthcare settings
